吡非尼酮联合醋酸泼尼松治疗特发性肺纤维化的临床疗效

Clinical efficacy of pirfenidone comined with prednisone acetate in the treatment of idiopathic pulmonary fibrosis

目的探讨吡非尼酮联合醋酸泼尼松治疗特发性肺纤维化(IPF)的临床效果。方法选取2018年1月—2021年3月大连市某医院收治的66例IPF患者为研究对象。采用随机数字表法将患者分为研究组和对照组,每组33例。对照组患者采用醋酸泼尼松治疗。研究组患者在对照组基础上采用吡非尼酮联合治疗。比较2组患者治疗前后第一秒用力呼气量(FEV_(1))、每分钟最大通气量(MVV)、呼气流量峰值(PEF)。比较2组患者治疗前后肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、免疫球蛋白E(IgE)水平。比较2组患者用药后不良反应发生情况。结果治疗前,2组患者FEV_(1)、MVV及PEF水平比较,差异无统计学意义(P>0.05)。治疗后,2组患者FEV_(1)、MVV及PEF水平均高于治疗前,且研究组高于对照组,差异均有统计学意义(P<0.05)。治疗前,2组患者TNF-α、IL-6及IgE水平比较,差异无统计学意义(P>0.05)。治疗后,2组患者TNF-α、IL-6及IgE水平均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05)。2组患者不良反应发生率比较,差异无统计学意义(P<0.05)。结论吡非尼酮联合醋酸泼尼松治疗IPF的临床效果显著,可有效改善患者的肺功能及TNF-α、IL-6及IgE水平,且安全性较高,具有较高临床应用价值。

Objective To investigate the clinical effect of pirfenidone combined with prednisone acetate in the treatment of idiopathic pulmonary fibrosis(IPF).Methods Sixty-six patients with IPF admitted to a hospital in Dalian from January 2018 to March 2021 were selected for the study.A random number table was used to divide the patients into a study group and a control group,with 33 cases in each group.Patients in the control group were treated with prednisone acetate,while patients in the study group were treated with pirfenidone combination therapy based on the control group.The forced expiratory volume in 1 second(FEV_(1)),maximal voluntary ventilation(MVV),and peak expiratory flow(PEF)were compared between the 2 groups before and after treatment.The levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and immunoglobulin E(IgE)were compared between the 2 groups before and after treatment.The occurrence of adverse reactions was compared between the 2 groups after drug administration.Results Before treatment,there was no statistically significant difference between the FEV_(1),MVV,and PEF levels in the 2 groups(P>0.05).After treatment,the levels of FEV_(1),MVV,and PEF in the 2 groups were higher than those before treatment,and higher in the study group than in the control group,with statistically significant differences(P<0.05).Before treatment,the levels of TNF-α,IL-6,and IgE in the 2 groups were compared,and the differences were not statistically significant(P>0.05).After treatment,the levels of TNF-α,IL-6,and IgE in the 2 groups were lower than before treatment,and the figures for the study group were lower than those for the control group.The differences were all statistically significant(P<0.05).The difference was not statistically significant(P>0.05)when comparing the incidence of adverse reactions in the 2 groups.Conclusion The clinical effect of pirfenidone combined with prednisone acetate in the treatment of IPF is significant,and it can effectively improve the lung function and TNF-α,IL-6,and IgE levels of patients while showing a high safety profile.Therefore,it holds considerable clinical value.